Biomedical Engineering Reference
In-Depth Information
[30] Wadia, J.S., Stan, R.V., and Dowdy, S.F., “Transducible TAT-HA fusogenic peptide
enhances escape of TAT-fusion proteins after lipid raft macropinocytosis,”
Nat Med
, Vol.
10, No. 3, 2004, pp. 310-5.
[31] Jones, A.T., “Macropinocytosis: searching for an endocytic identity and role in the uptake
of cell penetrating peptides,”
J Cell Mol Med
, Vol. 11, No. 4, 2007, pp. 670-84.
[32] Duchardt, F., et al., “A comprehensive model for the cellular uptake of cationic cell-
penetrating peptides,”
Traffic
, Vol. 8, No. 7, 2007, pp. 848-66.
[33] Fretz, M.M., et al., “Temperature-, concentration- and cholesterol-dependent translocation
of L- and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia
cells,”
Biochem J
, Vol. 403, No. 2, 2007, pp. 335-42.
[34] Maiolo, J.R., Ferrer, M., and Ottinger, E.A., “Effects of cargo molecules on the cellular
uptake of arginine-rich cell-penetrating peptides,”
Biochim Biophys Acta
, Vol. 1712, No. 2,
2005, pp. 161-72.
[35] Nakase, I., et al., “Cellular uptake of arginine-rich peptides: roles for macropinocytosis and
actin rearrangement,”
Mol Ther
, Vol. 10, No. 6, 2004, pp. 1011-22.
[36] Yang, S.R., et al., “Intracellular delivery enhancement of poly(amino acid) drug carriers by
oligoarginine conjugation,”
J Biomed Mater Res A
, Vol. 86, No. 1, 2008, pp. 137-48.
[37] Ruan, G., et al., “Imaging and tracking of tat peptide-conjugated quantum dots in living
cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding,”
J
Am Chem Soc
, Vol. 129, No. 47, 2007, pp. 14759-66.
[38] Youngblood, D.S., et al., “Stability of cell-penetrating peptide-morpholino oligomer
conjugates in human serum and in cells,”
Bioconjug Chem
, Vol. 18, No. 1, 2007, pp. 50-60.
[39] Vandenbroucke, R.E., et al., “Cellular entry pathway and gene transfer capacity of TAT-
modified lipoplexes,”
Biochim Biophys Acta
, Vol. 1768, No. 3, 2007, pp. 571-9.
[40] Fischer, R., et al., “A targeted protease substrate for a quantitative determination of protease
activities in the endolysosomal pathway,”
Chembiochem
, Vol. 7, No. 9, 2006, pp. 1428-34.
[41] Rinne, J., et al., “Internalization of novel non-viral vector TAT-streptavidin into human
cells,”
BMC Biotechnol
, Vol. 7, No. 2007, pp. 1.
[42] Hyndman, L., et al., “HIV-1 Tat protein transduction domain peptide facilitates gene
transfer in combination with cationic liposomes,”
J Control Release
, Vol. 99, No. 3, 2004,
pp. 435-44.
[43] Khalil, I.A., et al., “Octaarginine-modified multifunctional envelope-type nanoparticles for
gene delivery,”
Gene Ther
, Vol. 14, No. 8, 2007, pp. 682-9.
[44] Yamada, Y., et al., “MITO-Porter: A liposome-based carrier system for delivery of
macromolecules into mitochondria via membrane fusion,”
Biochim Biophys Acta
, Vol.
1778, No. 2, 2008, pp. 423-32.
[45] El-Andaloussi, S., et al., “Induction of splice correction by cell-penetrating peptide nucleic
acids,”
J Gene Med
, Vol. 8, No. 10, 2006, pp. 1262-73.
[46] Plank, C., et al., “The influence of endosome-disruptive peptides on gene transfer using
synthetic virus-like gene transfer systems,”
J Biol Chem
, Vol. 269, No. 17, 1994, pp.
12918-24.
[47] Sugita, T., et al., “Improved cytosolic translocation and tumor-killing activity of Tat-
shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2
peptide,”
Biochem Biophys Res Commun
, Vol. 363, No. 4, 2007, pp. 1027-32.
[48] Sirsi, S.R., et al., “Functionalized PEG-PEI copolymers complexed to exon-skipping
oligonucleotides improve dystrophin expression in mdx mice,”
Hum Gene Ther
, Vol. 19,
No. 8, 2008, pp. 795-806.
[49] Suk, J.S., et al., “Gene delivery to differentiated neurotypic cells with RGD and HIV Tat
peptide functionalized polymeric nanoparticles,”
Biomaterials
, Vol. 27, No. 29, 2006, pp.
5143-50.
Search WWH ::
Custom Search